239 related articles for article (PubMed ID: 25155368)
1. Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.
Jen MH; Kurth H; Iheanacho I; Dinet J; Gabriel S; Wasiak R; Jost WH
J Med Econ; 2014 Nov; 17(11):803-9. PubMed ID: 25155368
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
3. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.
Espay AJ; Trosch R; Suarez G; Johnson J; Marchese D; Comella C
Parkinsonism Relat Disord; 2018 Jul; 52():94-97. PubMed ID: 29530726
[TBL] [Abstract][Full Text] [Related]
4. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Tarsy D
Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
8. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
9. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia.
Skogseid IM; Malt UF; Røislien J; Kerty E
Eur J Neurol; 2007 Oct; 14(10):1129-37. PubMed ID: 17708754
[TBL] [Abstract][Full Text] [Related]
10. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
12. [Inter-rater reliability while using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in patients with cervical dystonia].
Kaji R; Osawa M; Yanagisawa N
Brain Nerve; 2009 Jan; 61(1):65-71. PubMed ID: 19177808
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
14. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia.
Barbosa PM; Rodrigues GR; de Oliveira DS; de Souza CP; Tumas V
Clin Neuropharmacol; 2015; 38(6):221-6. PubMed ID: 26536017
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.
Mordin M; Masaquel C; Abbott C; Copley-Merriman C
BMJ Open; 2014 Oct; 4(10):e005150. PubMed ID: 25324317
[TBL] [Abstract][Full Text] [Related]
17. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Samotus O; Lee J; Jog M
J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital.
Queiroz MR; Chien HF; Barbosa ER
Arq Neuropsiquiatr; 2011 Dec; 69(6):900-4. PubMed ID: 22297876
[TBL] [Abstract][Full Text] [Related]
19. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
Simonetta-Moreau M; Picaut P; Volteau M; Poewe W
Eur J Neurol; 2019 Jun; 26(6):943-e65. PubMed ID: 30168896
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
